The submission of a Marketing Authorization Application is a critical step towards getting a product approved for sale in a new market. For Outlook Therapeutics, this move indicates progress in the development and commercialization of ONS-5010. If approved, it could significantly impact the company's revenue and market position, especially in the treatment of Wet AMD, a major cause of blindness. The positive impact on the stock price in the short term is likely due to investor optimism about the potential market expansion and revenue growth.